As a team, we are accelerating the transfer of research discoveries – more accurate biomarkers for diagnosis and outcome prediction and novel therapeutics – from the “bench to the bedside” to make an impact on those living with cancer. Whether new discoveries begin at the bedside or the bench, our group is focused on understanding and ultimately improving the diagnosis and management of aggressive prostate cancer. Our multi-disciplinary group of more than 200 prostate cancer scientists, physicians, trainees and healthcare employees from five leading Alberta health research institutions are working with an international collaborative network to achieve our translational research goals – to make a meaningful impact on health policy and the outcomes of patients living with prostate cancer.
